Results 31 to 40 of about 16,507 (152)

Evidence for Aldosterone Antagonism in Heart Failure

Cardiac Failure Review
Activation of the renin–angiotensin–aldosterone system is the ultimate pathophysiological hallmark in heart failure. Though aldosterone primarily appears to regulate electrolyte homeostasis by acting on distal nephrons in the kidneys, its effects are far-
Rishi Sethi, Pravesh Vishwakarma, Akshyaya Pradhan   +2 more
doaj   +1 more source

Treatment and practical considerations of diabetic kidney disease

Frontiers in Medicine, 2023
Diabetic kidney disease (DKD) is a complication of diabetes that can lead to kidney failure. Over the years, several drugs have been developed to combat this disease.
Yara Bilen, Allaa Almoushref, Kenda Alkwatli, Omar Osman, Ali Mehdi, Hanny Sawaf   +5 more
doaj   +1 more source

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone

Clinical Pharmacokinetics, 2023
Finerenone, a selective and nonsteroidal antagonist of the mineralocorticoid receptor, has received regulatory approval with the indication of cardiorenal protection in patients with chronic kidney disease associated with type 2 diabetes. It is rapidly and completely absorbed and undergoes first-pass metabolism in the gut wall and liver resulting in a ...
Roland Heinig, Thomas Eissing
openaire   +2 more sources

Design, synthesis, and evaluation of naphthalidinamide analogues as nonsteroidal mineralocorticoid receptor antagonists

Journal of Chemical Research
Inappropriate overactivation of the mineralocorticoid receptor by the steroid hormones aldosterone or cortisol contributes to the development of cardiovascular diseases.
Mingguang Zhang, Yan Pang, Yurui Zhao, Sibei Chen, Cheng Guo   +4 more
doaj   +1 more source

Discontinuation of Heart Failure Pharmacotherapy in Older Adults With Frailty

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Guideline‐directed medical therapy (GDMT) improves outcomes in heart failure irrespective of frailty status. Nevertheless, the magnitude of frailty‐associated discontinuation of GDMT remains insufficiently studied.
Ryo Nakamaru, Shiori Nishimura, Hiraku Kumamaru, Kyohei Daigo, Kayo M. Walsh, Shun Kohsaka   +5 more
doaj   +1 more source

The impact of new tetralogy drugs on ventricular remodeling in heart failure patients: a systematic review and network meta-analysis

BMC Cardiovascular Disorders
Background Heart failure, particularly heart failure with reduced ejection fraction (HFrEF), represents a major global health challenge due to its high prevalence, rapid progression, and substantial mortality rates.
Xi-Wen Wang, Hao Li, Gan-Qi Wang, Ya-Nan Sheng, Xia Wang, Hui Pan, Zhi-Hao Wang, Wei Zhang, Yuan-Yuan Shang, Ming Zhong   +9 more
doaj   +1 more source

Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?

Kidney & Blood Pressure Research
Background: Aldosterone is the principal mineralocorticoid hormone and the final effector of the renin-angiotensin-aldosterone system. This hormone is primarily synthesized by the CYP11B2 enzyme and produced by the adrenal zona glomerulosa ...
Alessio Mazzieri, Francesca Timio, Francesco Patera, Francesco Trepiccione, Mario Bonomini, Gianpaolo Reboldi   +5 more
doaj   +1 more source

Mineralocorticoid Receptor Antagonist for Renal Protection

Renal Failure, 2012
The renin-angiotensin system (RAS) plays an important role in the pathophysiology of cardiovascular and renal diseases. In chronic kidney disease (CKD), blockade of RAS by angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) has been shown to reduce proteinuria and retard the progression of renal function deterioration ...
Terry King-Wing, Ma, Cheuk-Chun, Szeto
openaire   +2 more sources

A COMPARATIVE ASSESSMENT OF THE EFFECT OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON CHANGES IN GALECTIN-3 AND MMP-1 FIBROSIS MARKERS IN PATIENTS WITH CHRONIC CARDIAC FAILURE COMBINED WITH TYPE 2 DIABETES MELLITUS WITH MANIFESTATIONS OF MYOCARDIUM DYSSYNCHRONY

Journal of V. N. Karazin Kharkiv National University: Series Medicine, 2016
A comparative assessment of the effect of mineralocorticoid receptor antagonists on changes in galectin 3 and matrix metalloproteinase 1 fibrosis markers has been carried out on 106 examinations (average age (69 + 10.37) years) with type 2 DM and CCF of ...
T. A. Rudenko
doaj  

Hormone treatments in congestive heart failure

Journal of International Medical Research, 2018
The common ultimate pathological feature for all cardiovascular diseases, congestive heart failure (CHF), is now considered as one of the main public health burdens that is associated with grave implications. Neurohormonal systems play a critical role in
Lei Lei, Yuanjie Mao
doaj   +1 more source